WO2001005384A3 - Manumycin derivatives for treating parasitic disorders - Google Patents

Manumycin derivatives for treating parasitic disorders Download PDF

Info

Publication number
WO2001005384A3
WO2001005384A3 PCT/GB2000/002694 GB0002694W WO0105384A3 WO 2001005384 A3 WO2001005384 A3 WO 2001005384A3 GB 0002694 W GB0002694 W GB 0002694W WO 0105384 A3 WO0105384 A3 WO 0105384A3
Authority
WO
WIPO (PCT)
Prior art keywords
ring
compound
manumycin
derivatives
treating parasitic
Prior art date
Application number
PCT/GB2000/002694
Other languages
French (fr)
Other versions
WO2001005384A2 (en
Inventor
Mark Christian Field
Bassam Rushdi Said Ali
Original Assignee
Imperial College
Mark Christian Field
Bassam Rushdi Said Ali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College, Mark Christian Field, Bassam Rushdi Said Ali filed Critical Imperial College
Priority to AU61689/00A priority Critical patent/AU6168900A/en
Publication of WO2001005384A2 publication Critical patent/WO2001005384A2/en
Publication of WO2001005384A3 publication Critical patent/WO2001005384A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided use of a compound in the manufacture of a medicament to treat or prevent a protozoan parasitic disorder; wherein the compound is a compound of formula (I) wherein: R is a ring structure comprising at least 1 carbon atom in the ring; X is a carboxyl group substituent on the ring R; Y is a nitrogen group on the ring R; Z is an oxygen containing group substituent on the ring R; wherein the ring R may be further optionally substituted, or a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable solvate of the compound or the salt.
PCT/GB2000/002694 1999-07-15 2000-07-13 Manumycin derivatives for treating parasitic disorders WO2001005384A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61689/00A AU6168900A (en) 1999-07-15 2000-07-13 Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9916647.2A GB9916647D0 (en) 1999-07-15 1999-07-15 Compounds
GB9916647.2 1999-07-15

Publications (2)

Publication Number Publication Date
WO2001005384A2 WO2001005384A2 (en) 2001-01-25
WO2001005384A3 true WO2001005384A3 (en) 2001-05-25

Family

ID=10857319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002694 WO2001005384A2 (en) 1999-07-15 2000-07-13 Manumycin derivatives for treating parasitic disorders

Country Status (3)

Country Link
AU (1) AU6168900A (en)
GB (1) GB9916647D0 (en)
WO (1) WO2001005384A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2390245A1 (en) * 2010-05-26 2011-11-30 Nabriva Therapeutics AG Enantiomerically pure amines
CA2887913A1 (en) 2012-10-10 2014-04-17 Arizona Board Of Regents On Behalf Of Arizona State University Multifunctional radical quenchers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456474A1 (en) * 1990-05-10 1991-11-13 Kyowa Hakko Kogyo Kabushiki Kaisha UCF1 compounds derivatives thereof and processes for their preparation
JPH07112930A (en) * 1993-10-14 1995-05-02 Kyowa Hakko Kogyo Co Ltd Cell proliferation inhibitor for vascular smooth muscle
US5444087A (en) * 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds
EP0670317A1 (en) * 1993-09-22 1995-09-06 Kyowa Hakko Kogyo Co., Ltd. Epoxycyclohexenedione derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456474A1 (en) * 1990-05-10 1991-11-13 Kyowa Hakko Kogyo Kabushiki Kaisha UCF1 compounds derivatives thereof and processes for their preparation
EP0670317A1 (en) * 1993-09-22 1995-09-06 Kyowa Hakko Kogyo Co., Ltd. Epoxycyclohexenedione derivative
JPH07112930A (en) * 1993-10-14 1995-05-02 Kyowa Hakko Kogyo Co Ltd Cell proliferation inhibitor for vascular smooth muscle
US5444087A (en) * 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALCARAZ L ET AL: "Synthetic Approaches to the Manumycin A, B and C Antibiotics: The First Total Synthesis of (+)-Manumycin A", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 55, no. 12, 19 March 1999 (1999-03-19), pages 3707 - 3716, XP004158776, ISSN: 0040-4020 *
KAPFER I ET AL: "The Synthesis of Novel Analogues of the Manumycin Family of Antibiotics and the Antitumour Antibiotic LL-C10037alpha", TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 37, no. 12, 18 March 1996 (1996-03-18), pages 2101 - 2104, XP004029872, ISSN: 0040-4039 *
MACDONALD G ET AL: "Asymmetric Synthesis of the mC7N Core of the Manumycin Family: Preparation of (+)-MT 35214 and a Formal Total Synthesis of (-)-Alisamycin", TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 39, no. 30, 23 July 1998 (1998-07-23), pages 5433 - 5436, XP004123252, ISSN: 0040-4039 *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 08 29 September 1995 (1995-09-29) *

Also Published As

Publication number Publication date
WO2001005384A2 (en) 2001-01-25
AU6168900A (en) 2001-02-05
GB9916647D0 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
CA2183655A1 (en) 4-polycyclic amino-substituted quinazoline derivatives
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
AU1025795A (en) Prolineamide derivatives
EP1550662A4 (en) Novel adenine compound and use thereof
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
CA2102591A1 (en) Hypoglycemic Agent
CA2143864A1 (en) Morphinan derivatives and pharmaceutical use thereof
YU69902A (en) New piperazine derivatives
AU8047294A (en) Methods of treating menstrual symptoms and compositions therefore
AU5910996A (en) Pyrrole derivatives and medicinal composition
AU7583494A (en) Methods of inhibiting uterine fibrosis
AU8154794A (en) Methods of inhibiting seborrhea and acne
BRPI0409959A (en) use of azetidinecarboxamide derivatives in therapy
AU8156394A (en) Methods for inhibiting LDL oxidation and atheroclerosis
AU7579194A (en) Methods for inhibiting angiogenisis and angiogenic diseases
EP0712844A4 (en) Novel fused-ring carboxylic acid compound or salt thereof, and medicinal use thereof
GB9318935D0 (en) Heterocyclic derivatives
DK0652002T3 (en) Use of 2-phenyl-3-aroylebenzothiophenes in the manufacture of a drug for inhibiting cartilage degradation
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
AU3626895A (en) Quinazolinone pharmaceuticals and use thereof
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
UA41880C2 (en) Serotoninergic derivatives of ergolin and a pharmaceutical composition
WO2001005384A3 (en) Manumycin derivatives for treating parasitic disorders
WO2005053702A3 (en) Anti-inflammatory agents
CA2382654A1 (en) Novel a-500359 derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP